Company profile: Cybin
1.1 - Company Overview
Company description
- Provider of clinical-stage psychedelic-based therapeutics for mental health conditions, including CYB003, a deuterated psilocybin analog for Major Depressive Disorder with positive Phase 2 data, and CYB004, a deuterated DMT molecule aimed at treating Generalized Anxiety Disorder, with a US Phase 2 study expected to begin.
Products and services
- Clinical-Stage Psychedelic Therapeutics Development: Clinical-stage program that creates safe and effective psychedelic-based therapeutics to address the large unmet need for innovative treatment options for mental health conditions
- CYB003: A deuterated psilocybin analog engineered for treating Major Depressive Disorder, demonstrating positive Phase 2 clinical data in a clinical-stage program for psychedelic-based therapeutics
- CYB004: A deuterated DMT molecule architected to address Generalized Anxiety Disorder, with a US Phase 2 study expected to begin, advancing clinical-stage psychedelic therapeutic development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cybin
Biohaven Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for neurological diseases, including rare disorders. Focuses on CGRP receptor antagonists, glutamate modulators and a myeloperoxidase inhibitor. Portfolio includes Nurtec ODT and Zavzpret for migraine, and pipeline candidates troriluzole, BHV-7000, taldefgrobep and BHV-2100 for OCD, SCA, epilepsy, bipolar disorder, SMA, obesity and neuropathic pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biohaven Pharmaceuticals company profile →
Neuraxpharm
HQ: Germany
Website
- Description: Provider of branded and generic CNS pharmaceuticals and nutraceuticals in main European countries, developing and commercializing products for CNS disorder prevention and treatment. Develops and manufactures finished dosage forms (mainly solid oral) for CNS and other areas; includes Buccolam for acute pediatric seizures and Preventan for immune support. Also offers LepsiApp for epilepsy management, R&D (actives, bioequivalence, regulatory), and pharmacovigilance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuraxpharm company profile →
Conformal Medical
HQ: United States
Website
- Description: Provider of transcatheter left atrial appendage occlusion solutions to prevent stroke in patients with nonvalvular atrial fibrillation, including the Conformal Left Atrial Appendage System (CLAAS) implant and the CONFORM clinical trial evaluating CLAAS versus other commercially available LAAO devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Conformal Medical company profile →
Autobahn Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage restorative treatments for neuropsychiatric and neuroimmunologic disorders, including ABX-002 (CNS-directed TRβ agonist for major depressive disorder), ABX-003 (next-generation TRβ-selective thyromimetic in IND-enabling studies), ABX-101 (S1P receptor modulator with neuroinflammatory and neuroprotective benefits), and a brain-targeting chemistry platform for tailored CNS/peripheral drug exposure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Autobahn Therapeutics company profile →
InNeuroCo
HQ: United States
Website
- Description: Provider of complex catheter solutions for neurovascular applications, delivering design and development of medical devices, ISO-certified contract manufacturing and assembly for the neurovascular industry, and regulatory submissions support with over 20 submissions in the US, Europe, and Asia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InNeuroCo company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cybin
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cybin
2.2 - Growth funds investing in similar companies to Cybin
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cybin
4.2 - Public trading comparable groups for Cybin
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →